CORolla™ TAA for Heart Failure and Preserved Ejection Fraction and Diastolic Dysfunction
NCT ID: NCT01956526
Last Updated: 2013-10-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
12 participants
INTERVENTIONAL
2013-08-31
2017-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CORolla™ TAA Stand Alone
Single arm study design including with patients with isolated HFpEF, in NYHA f. Cl. III-IV. These patients will receive the CORolla™ TAA device. For assessments of results, intra-patient comparisons of pre-procedure and follow-up data will be performed;
CORolla™ TAA device
AVR and CORolla™ TAA Add On group
patients who require aortic valve replacement (AVR) due to aortic stenosis and have diastolic dysfunction will receive the CORolla™ TAA device.
CORolla™ TAA device
AVR and CORolla ADD On - Control
patients who require only the aortic valve replacement (AVR) due to aortic stenosis and have diastolic dysfunction.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CORolla™ TAA device
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult (age \> 18 years)
* Diagnosis of heart failure with preserved systolic function according with ESC 2008 Guidelines (ejection fraction ≥ 50%)
* NYHA F. Class III or IV symptoms with history of previous heart failure hospitalization in the last year
* Able to sign informed consent and return for follow-up visits.
* No contraindication for anticoagualation and antiplatelet treatment.
* Cardiac medications unchanged for greater than 4 weeks (not including diuretics)
* Pulmonary Wedge pressure \> 15 mmHg documented by right heart catheterization at enrollment.
* Echocardiographic criteria
* Preserved regional wall motion (no wall motion abnormalities).
* Left ventricular ejection fraction ≥ 50%
* LV end-diastolic volume index (LVEDVI) \<97 ml/m2.
* Left Atrial Volume Index: (LAVi \>29 ml/m2).
* E/E' ratio ( mean of septal and lateral ) ≥12 (applicable only to patients with sinus rhythm)
* No intra-cardiac thrombus.
* Minimal endocardial height from Apex to Mitral Annulus ≥ 70mm.
Exclusion Criteria
* Uncontrolled HTN defined as \> 140/90 mmHg, or \>160/90 mmHg for patients on 3-drug therapy
* Current or anticipated need for ICD, currently implanted with a cardiac resynchronization device (CRT), left ventricular assist device (LVAD).
* Within the past 3 months - Acute myocardial infarction (AMI), cerebral vascular accident (CVA), Transient Ischemic Attack (TIA) , Percutaneous coronary intervention (PCI or transmyocardial laser revascularization (TMR or PMR)
* Valvular disease (unless add - on to aortic valve replacement due to aortic stenosis)
* Hypertrophic cardiomiopathy
* Pericardial disease
* Cor pulmonale or other cause of isolated right heart failure.
* Non reversible pulmonary hypertension.
* Right ventricle failure or right ventricular myocardial infarction.
* Infiltrative heart disease
* Non-cardiovascular disease
* Non-cardiovascular condition limiting ability to assess the 6-minute hall walk test
* Prior surgery, radiation, or thoracic surgery limiting the ability to place the device
* Body mass index of greater than 40
* Uncontrolled hyperglycemic status as addressed by HbA1c \>8.5%
* Asthma COPD (e.g. FEV1 \<1.5 liter), or severe restrictive lung disease
* Severe chronic renal failure indicated by MDRD GFR \<30 mL/min/1.73 m2
* Liver impairment addressed by bilirubin \> 2 mg/dl and or pseudo- colinesterasis plasma concentration \< 1500 IU and/or abnormal coagulative profile
* Severe anemia addressed by Hb concentration \<10 gr/l.
* Solid organ or hematologic transplant.
* Previous Trans Apical procedures/implantation
* Miscellaneous conditions
* Unwilling to fulfill the protocol medication compliance, testing, and follow-up requirements
* Co-morbid condition that in the physician's opinion would prohibit the subject's ability to meet the protocol requirements
* Pregnancy at the time of enrollment. (Women of child bearing potential must have a negative serum pregnancy test within two weeks prior to enrollment, or be using hormonal contraceptives or intrauterine devices)
* Enrolled in another investigational study
* A history of alcohol abuse, drug addiction, or other psychosocial condition that would preclude successful participation, or clear judgment and informed consent in the opinion of the Principal Investigator
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CorAssist Cadiovascular Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Spedali Civili - Brescia Hospital
Brescia, , Italy
Multimedica
Milan, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Claudio Muneretto, M.D. Prof.
Role: primary
Laura Tononi
Role: backup
Edoardo Gronda, M.D. Prof.
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K; ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008 Oct;29(19):2388-442. doi: 10.1093/eurheartj/ehn309. Epub 2008 Sep 17. No abstract available.
Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbely A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007 Oct;28(20):2539-50. doi: 10.1093/eurheartj/ehm037. Epub 2007 Apr 11.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLD CRL 0403
Identifier Type: -
Identifier Source: org_study_id